Navigation Links
Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Date:5/29/2009

KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor

NEW YORK, May 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, as a treatment for advanced renal cell carcinoma. Abstract #5034, entitled, "Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor," was presented earlier today in a poster session at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Orlando, Florida. Later this afternoon, the data will also be presented by Dr. Brian Rini, Associate Professor of Medicine at the Cleveland Clinic Taussig Cancer Institute, in a poster discussion during the Genitourinary Cancer session.

The study enrolled a total of 50 patients, of which 46 patients were evaluable for response. Evaluable patients were defined as those who had greater than 7 days of treatment. The primary endpoint of this study was clinical benefit, defined as response rate (RECIST), and progression-free survival (PFS) in RCC patients who failed a prior VEGF receptor inhibitor (sunitinib or sorafenib). Safety of perifosine in this patient population was evaluated as a secondary endpoint. Best response to single agent perifosine was as follows:

      Group     N       PR      SD > 12 wks    CBR*       Median PFS
                       N (%)       N (%)       N (%)       (SD or >)
     All Pts    46    5 (11%)    16 (35%)    21 (46%)      33 weeks
                                                      [95% CI (24, 
'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
2. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
6. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
7. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
11. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015  MEI Pharma, Inc. (Nasdaq: MEIP ... novel therapies for cancer, announced today that Daniel P. ... at the Cowen and Company 35 th Annual Health ... Eastern time from the Boston Marriott Copley Place. A live ... . A replay will be available approximately one hour after ...
(Date:2/26/2015)... 26, 2015  Unetixs Vascular Inc, the ... physiologic testing solutions, today announced a partnership ... highly innovative medical imaging company that invented ... SuperSonic Imagine,s technology to more customers in ... Aixplorer Ultrasound System combines exceptional image quality ...
(Date:2/26/2015)... Cyberonics, Inc. (NASDAQ: CYBX ) today announced results ... highlights 1 Operating results for the third quarter of fiscal ... other achievements include: , Worldwide net sales of $72.1 ... , U.S. net sales reached $57.6 million, an increase of ... the single country order, international sales increased by 18% on ...
Breaking Medicine Technology:MEI Pharma to Present at Cowen and Company Health Care Conference 2MEI Pharma to Present at Cowen and Company Health Care Conference 3Unetixs Vascular Announces Partnership with SuperSonic Imagine 2Unetixs Vascular Announces Partnership with SuperSonic Imagine 3Cyberonics Reports Fiscal 2015 Third Quarter Results 2Cyberonics Reports Fiscal 2015 Third Quarter Results 3Cyberonics Reports Fiscal 2015 Third Quarter Results 4Cyberonics Reports Fiscal 2015 Third Quarter Results 5Cyberonics Reports Fiscal 2015 Third Quarter Results 6Cyberonics Reports Fiscal 2015 Third Quarter Results 7Cyberonics Reports Fiscal 2015 Third Quarter Results 8Cyberonics Reports Fiscal 2015 Third Quarter Results 9Cyberonics Reports Fiscal 2015 Third Quarter Results 10Cyberonics Reports Fiscal 2015 Third Quarter Results 11Cyberonics Reports Fiscal 2015 Third Quarter Results 12Cyberonics Reports Fiscal 2015 Third Quarter Results 13Cyberonics Reports Fiscal 2015 Third Quarter Results 14Cyberonics Reports Fiscal 2015 Third Quarter Results 15Cyberonics Reports Fiscal 2015 Third Quarter Results 16Cyberonics Reports Fiscal 2015 Third Quarter Results 17Cyberonics Reports Fiscal 2015 Third Quarter Results 18Cyberonics Reports Fiscal 2015 Third Quarter Results 19
(Date:2/26/2015)... 2015 Wound Care Advantage ... expanded its executive team by adding three key members ... the same time two WCA team members were promoted ... (WCA) was founded in 2002 and is one of ... The WCA team believes that providing outstanding patient care ...
(Date:2/26/2015)... 2015 Catalent Pharma Solutions, ... technologies and development solutions for drugs, biologics ... several expanded capabilities within its European Clinical ... implemented in response to increased customer demand ... of highly-potent or temperature-sensitive investigational medical products ...
(Date:2/26/2015)... The Reproductive Science Center of New Jersey ... in Lawrenceville, NJ. , Dr. Ziegler and ... physicians, and NJ Top Docs, have been recognized for ... of infertility and reproductive medicine. This dedicated team of ... providing current, high quality medical treatments to their patients ...
(Date:2/26/2015)... February 26, 2015 A tummy tuck ... accomplish two different things—but they can be combined to ... tummy tuck with liposuction, Michigan’s Dr. Pramit Malhotra calls ... seen grow in popularity by 50 percent in the ... more patients seeking to combine the two? First, it ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Kantar Health ... in The Sunday Times “100 Best Small Companies to Work ... Health UK has been included on the list, which measures ... a fantastic team here at Kantar Health UK, and we ... list,” Kantar Health UK CFO Mark Hinton-Jones said. “The team ...
Breaking Medicine News(10 mins):Health News:Wound Center Management Leader WCA Expands Its Team to Include Additional Industry Experts 2Health News:Wound Center Management Leader WCA Expands Its Team to Include Additional Industry Experts 3Health News:Wound Center Management Leader WCA Expands Its Team to Include Additional Industry Experts 4Health News:Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling 2Health News:Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling 3Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 3Health News:Dr. Pramit Malhotra Reports a Rise in Patients Combining Liposuction and Tummy Tuck in Michigan, Citing the “Power LipoTuck” 2Health News:Dr. Pramit Malhotra Reports a Rise in Patients Combining Liposuction and Tummy Tuck in Michigan, Citing the “Power LipoTuck” 3Health News:Kantar Health UK Named One of The Sunday Times 100 Best Small Companies to Work For 2
... has spearheaded clinical research to cure osteoarthritis without surgery ... walk again, holding// out promise of relief to the ... the first of its kind in the world, the ... tissues that wear and tear due to ageing. ...
... liver from fatty foods that we eat. A certain amount// of ... to keep the body healthy but a high level can lead ... to a build up of small fatty lumps developing on the ... ,We are at greater risk if we smoke, have high blood ...
... A senior judge of Pakistan has ordered woman lawyers ... Times reported Saturday//. ,"You are professionals and should ... Pervaiz Khan of the Peshawar High Court told veiled ... ,"We (the judges) cannot identify veiled woman lawyers and ...
... 1906. One hundred years after its first diagnosis, researchers ... in an effort to understand the manner in which ... Primate Research Center, Emory University, feel that this study ... this progressive brain disorder. About 20 million Americans are ...
... fast food industry which has been simmering in the trans-fat ... tables on their sticky ally- the hydrogenated// vegetable oils! This ... ,KFC, Marks & Spencer, Asda, Sainsbury’s and Tesco have already ... categories. The British Medical Journal has urged the Government to ...
... ‘Men’s Health’, a mega lifestyle magazine for men with a ... findings of a survey that queried almost 40,000 men// from ... exclusive feature titled "World's Best Sex Right Here in India" ... survey. ,Nearly 75% of the Indian men surveyed ...
Cached Medicine News:Health News:Indian radiologist spearheads cure for osteoarthritis sans surgery 2Health News:Indian radiologist spearheads cure for osteoarthritis sans surgery 3
... The PowerEase® 500 Power ... mini-gel electrophoresis. It offers extensive ... and four custom methods for ... own preferences. The simple, intuitive ...
Power Supply E865 is ideal for electrophoresis and semi-dry blotting applications. The electrical leads from Hoefer Gel apparatus are fully compatible with this new E865 power supply and there is no ...
EPS 3501 : 3500 V, 150 mA, 100 W maximum. Constant voltage, constant current, or constant power modes. Stores and recalls three protocols. Excellent for manual DNA sequencing and IEF applications....
... supply, with temperature probe, 100-120 and 220-240 V, ... mA, and 400 W. The temperature probe is ... 90 degrees C during electrophoresis. Built-in infrared capability ... instructions are provided. Dimensions are 27.5 x 34 ...
Medicine Products: